It is provided in a controlled, research-grade format suitable for laboratory use, including the reconstitution and handling of compounds for analysis
The 100-day return window and current $99.95 pricing reflect today's market
Ipamorelin (INN) (developmental code name NNC 26-0161) is a peptide selective agonist of the ghrelin/growth hormone secretagogue receptor (GHS) and a growth hormone secretagogue.[2][3] It is a pentapeptide with the amino acid sequence Aib-His-D-2-Nal-D-Phe-Lys-NH2 that was derived from GHRP-1.[4] Ipamorelin significantly increases plasma growth hormone (GH).[1][3][5] In addition, ipamorelin stimulates body weight gain in animals.[5] Like pralmorelin and GHRP-6, ipamorelin does not affect prolactin, follicle-stimulating hormone (FSH), luteinizing hormone (LH), or thyroid-stimulating hormone (TSH) levels.[3] However, unlike pralmorelin (GHRP-2) and GHRP-6, but similarly to growth hormone-releasing hormone (GHRH), ipamorelin does not stimulate the secretion of adrenocorticotropic hormone (ACTH) or cortisol, and is highly selective for inducing the secretion only of GH.[3] Ipamorelin Peptide is under active investigation in a number of cell culture and animal models
doi: 10.1002/(ISSN)1097-0142 10 MehraraBJGreeneAK
13 The first four trials were designed primarily to assess cardiovascular safety in patients with T2D and yielded unexpected beneficial results
